Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Abbott Laboratories : Gets FDA Breakthrough Designation for Fully Implantable Heart-Pump System

share with twitter share with LinkedIn share with facebook
share via e-mail
02/04/2020 | 09:36am EDT

By Colin Kellaher

Abbott (ABT) on Tuesday said it received breakthrough-device designation from the U.S. Food and Drug Administration for its fully implantable heart-pump system.

The Abbott Park, Ill., maker of healthcare products said its Fully Implantable Left Ventricular Assist System, which is currently in development, would mean more freedom and a greater quality of life for patients because there are no external components.

Abbott said current left-ventricular-assist devices are implanted into the body and then powered using an external battery pack or charging port.

The FDA's breakthrough-devices program aims to expedite the development and review of technology that offers significant advantages over existing approved products.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBOTT LABORATORIES
03/31ABBOTT LABORATORIES : Medical Companies Win Approval for Rapid Coronavirus Tests..
DJ
03/31ABBOTT LABORATORIES : Thinking about trading options or stock in Abbott Laborato..
PR
03/30Abbott, Johnson & Johnson rise; SeaWorld, Carnival Fall
AQ
03/30ABBOTT LABORATORIES : Shares Rise With Rollout of Rapid Covid-19 Test
DJ
03/30ABBOTT LABORATORIES : Medical Companies Win Approval for Rapid Coronavirus Tests
DJ
03/30GLOBAL MARKETS LIVE: Government and central banks urge banks and businesses t..
03/30ABBOTT LABORATORIES : Launches molecular point-of-care test to detect novel coro..
AQ
03/27ABBOTT : Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as..
PR
03/27Transmission of Annual Report for the Year Ended December 31, 2019 of Abbott ..
AQ
03/19ABBOTT : Hosts Conference Call for First-Quarter Earnings
PR
More news
Financials (USD)
Sales 2020 33 121 M
EBIT 2020 7 112 M
Net income 2020 4 206 M
Debt 2020 10 715 M
Yield 2020 1,80%
P/E ratio 2020 32,6x
P/E ratio 2021 26,3x
EV / Sales2020 4,52x
EV / Sales2021 4,04x
Capitalization 139 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 94,53  $
Last Close Price 78,91  $
Spread / Highest target 39,4%
Spread / Average Target 19,8%
Spread / Lowest Target -1,15%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President, Chief Operating Officer & Director
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES-9.15%139 153
MASIMO CORPORATION12.06%9 528
NOVOCURE LIMITED-20.09%6 710
ASAHI INTECC CO., LTD.-2.09%6 468
GETINGE9.60%5 228
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.-1.14%5 136